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ABSTRACT: Background: The clinical demarcation
of the syndrome progressive myoclonus ataxia is
unclear, leading to a lack of recognition and difficult dif-
ferentiation from other neurological syndromes.
Objectives: The objective of this study was to apply a
refined definition of progressive myoclonus ataxia and
describe the clinical characteristics in patients with progres-
sivemyoclonus ataxia andwith isolated corticalmyoclonus.
Methods: A retro- and prospective analysis was per-
formed in our tertiary referral center between 1994 and
2014. Inclusion criteria for progressive myoclonus ataxia
patients were the presence of myoclonus and ataxia
with or without infrequent (all types, treatment respon-
sive) epileptic seizures. Inclusion criteria for isolated
cortical myoclonus was the presence of isolated cortical
myoclonus. Clinical and electrophysiological character-
istics data were systematically scored.
Results: A total of 14 progressive myoclonus ataxia
patients (males, 7; females, 7), median age 14.5 years,
and 8 isolated cortical myoclonus patients (males, 2;
females, 6), median age 23.5 years, were identified. In
93% of the progressive myoclonus ataxia patients,
ataxia started first (median 2 years) followed by
myoclonus (4 years) and finally infrequent epilepsy (9.3
years), with a progressive course in 93%. In 64% of the
progressive myoclonus ataxia patients, a genetic under-
lying etiology was identified, including 3 not earlier
reported causative progressive myoclonus ataxia genes.
In isolated cortical myoclonus patients, myoclonus
started at (median) 12 years with progression over time
in 63% and a single epileptic seizure in 1 patient. No
genetic causes were identified.
Conclusion: Using a refined definition, we could create a
rather homogenous progressive myoclonus ataxia group.
Patients with isolated cortical myoclonus have a different
course and do not appear to evolve in progressive myoc-
lonus ataxia. The refined progressive myoclonus ataxia
definition is a successful first step toward creating a sep-
arate syndrome for both clinical practice and future
genetic research. VC 2018 The Authors. Movement Disor-
ders published by Wiley Periodicals, Inc. on behalf of
International Parkinson and Movement Disorder Society.
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Progressive myoclonus ataxia (PMA) is a rare disorder
and defined in the literature as progressive ataxia and
myoclonus, without prominent decline in cognitive func-
tions, and with or without infrequent epileptic seizures.1
PMA was previously known as the Ramsay Hunt syn-
drome, named after sir James Ramsay Hunt who first
described this triad of symptoms in 1921.2 PMA can be
acquired as in celiac disease but is mainly caused by
genetic disorders, including inborn errors of metabolism
and neurodegenerative disorders, such as myoclonic epi-
lepsy with ragged red fibers syndrome and North Sea
progressive myoclonus epilepsy.3 Despite the suspicion
of a genetic cause, only in less than 50% a causative
genetic defect can be identified.4 Identification of an etio-
logical cause is important as some disorders require spe-
cific treatment and also with regard to the patient’s
prognosis and appropriate genetic counseling.
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As a clear demarcation of clinical features of PMA
is absent, problems arise regarding the recognition
and differentiation of PMA from other neurological
syndromes. PMA can especially be hard to distin-
guish from the related but more extensively studied
progressive myoclonus epilepsy (PME) syndrome.
PMA and PME syndromes are characterized by the
combination of myoclonus, ataxia, and epilepsy and
mainly differ in the severity of specific features. By
definition, PME patients compared to PMA present
with more prominent (frequent) epilepsy and have in
addition, severe cognitive deterioration.1 It is unclear
where to draw the line between infrequent and fre-
quent epilepsy and if (mild) cognitive decline should
be part of the PMA criteria. In the past, the difficul-
ties in discriminating PME and PMA led to a discus-
sion between experts from the epilepsy field arguing
for lumping, whereas movement disorder experts
favored splitting.5,6 Recently, this discussion
restarted in the disorder North Sea PME caused by a
mutation in the Golgi SNAP receptor complex 2 gene
(GOSR2) gene, which is described both as PMA and
PME in the literature.7,8
The aim of the present study is to apply refined clinical
criteria for PMA in a Dutch cohort of patients presented
in a tertiary movement disorder clinic. The criteria
include symptoms of ataxia and myoclonus and a clear
definition of infrequent epilepsy, comprising of
treatment-responsive epilepsy enfolding all seizure types.
We do not define the decline in cognitive functions.
PMEs are known to progress into refractory epilepsy (fre-
quent epilepsy) and can even result in death as a result of
status epilepticus; therefore, the response on appropriate
antiepileptic therapy can be used as feature of infrequent
epilepsy and hence PMA.9 Compared to previous criteria
of PMA in which only tonic-clonic seizures were taken
into account, we included all seizure types because differ-
ence in type is not associated with difference in health-
related quality of life (HRQoL) and should not determine
severity of epilepsy.10,11
In this study, we focus on the clinical and electro-
physiological features and the detected etiology and
expect that this will lead to a homogenous group of
PMA patients with different genetic causes. At the
onset of symptoms, the severity and course of PMA
are not always clear in an individual patient. We
therefore also include patients with isolated cortical
myoclonus (ICM) as little is known in the literature of
this group of patients. By including ICM patients we
can study if the course of ICM and PMA is similar or
different and determine if ICM can be a potential pre-
decessor of the devastating PMA syndrome. The clus-
tering of rare patients facilitates future genetic
research with the ultimate goal of insight in the
pathology and increase the diagnostic yield in patients
with suspected genetic causes of PMA.
Methods
A retrospective analysis was performed of PMA and
ICM patients who visited the University Medical Cen-
ter of Groningen (Groningen, The Netherlands) in the
period 1994 to 2014. In addition, we prospectively
included PMA and ICM patients visiting the outpa-
tient clinic between June 2014 and January 2017. The
medical ethical committee of the University Medical
Center of Groningen approved this study (no.
2014.256).
To identify patients presenting with PMA, the terms
“myoclonus” AND “ataxia” were used when search-
ing the hospital’s electronic database. Patients of all
ages were included. Inclusion criteria for PMA syn-
drome were based on the following criteria: (1) the
presence of myoclonus, (2) the presence of ataxia, and
(3) no or infrequent epilepsy (treatment-responsive
epilepsy including all types of epileptic seizures). These
criteria were partly derived from the most recent defi-
nition stated by the Marseille Consensus Group in
1990. We changed the criteria in three ways. We left
out progression of core features and deterioration of
cognitive function as essential criteria. The third dif-
ference is the specification of infrequent epilepsy
(Table T11).1
To identify ICM patients, a retrospective analysis
was performed using the Clinical Neurophysiological
database for those in whom video polymyography was
part of the routine diagnostic workup. The electro-
physiological diagnosis of cortical myoclonus required
a burst duration below 100 ms and is supported by
(1) the presence of action-induced or stimulus-sensitive
myoclonic jerks, (2) a (multi)focal distribution pre-
dominantly affecting the face and distal limbs, (3) the
presence of negative myoclonus, (4) confirmation of
the cortical origin with back averaging, coherence
analysis, and/or somatosensory evoked potential.12
We systematically scored the following clinical char-
acteristics: age, gender, age at onset, age at examina-
tion, family history, progression of motor symptoms,
onset of myoclonic/ataxic symptoms, distribution of
myoclonus/ataxia, stimulus sensitivity and provoking
factors of myoclonus, frequency of epilepsy, severity
TABLE 1. A short overview of criteria included in the
refined definition we proposed in this study compared to
the definition stated by the Marseille Consensus Group






All types of seizures

Mild cognitive decline  
Progressive course  
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of cognitive decline, psychiatric symptoms, oculomo-
tor abnormalities, and underlying etiology. The sever-
ity of cognitive decline was based on the expert
opinion stated by the neurologists in clinical notes.
The following features of polymyography, if applied,
were also systematically scored: burst duration, pres-
ence of negative myoclonus, and, if present, back aver-
aging, coherence analysis, and somatosensory evoked
potential.
Statistical Analysis
Using IBM SPSS Statistics version 23 (Armonk, New
York, USA), descriptive statistics were used to study
discriminative features between patients presenting
with PMA and patients with ICM.
Results
Patients
A total of 38 patients were identified suffering from
myoclonus and ataxia, of which 14 patients were con-
sidered to adhere to the refined definition of PMA. A
total of 30 patients were identified with cortical myoc-
lonus, 8 of which with ICM. Patients were excluded
in case insufficient information was available (n55),
another movement disorder (dystonia, chorea, tics,
tremor and parkinsonian signs) was present (n5 19),
or an acquired etiology was causative of the move-
ment disorder (n5 8). Following the diagnostic algo-
rithm of myoclonus, an acquired etiology was ruled
out if the use of medication or toxic agents, laboratory
test, and MRI were not explanatory for the myoclonic
jerks.13 Furthermore, the presence of prominent epi-
lepsy was reason for exclusion in case of refractory
epilepsy (frequent epilepsy; n54) or in case of epi-
lepsy being reason for initial referral (n510), as this
study is from the perspective of the movement disor-
der clinician (Supplemental Figure 1).
Table T22 gives an overview of the clinical characteris-
tics. An extensive summary of the individual patients
is given in Supplemental Table 1.
PMA
The 14 PMA patients (males, 7; females, 7) had a
median age of 14.5 years (interquartile range [IQR]
7.3-31). In 13 patients, the presenting symptom was
reported, of whom 11 patients started with ataxic
symptoms, 1 patient with myoclonic jerks, and 1 with
simultaneously ataxic and myoclonic symptoms. The
ataxic symptoms started at the median age of 2 years
(IQR 1-2.3). The onset was gradual, with both upper
and lower limb involvement in 11, an ataxic gait in
14, and dysarthria in 10 cases. At the median age of 4
years (IQR 2.3-6) myoclonus started with a gradual
onset, worsening during action and most commonly
affecting the upper limbs. Myoclonus was stimulus
sensitive (somatosensory and auditory) in 4 cases, and
negative myoclonus was seen in 6 cases. In 4 patients,
infrequent epilepsy was observed starting at a median
age of 9.3 years (IQR 6-11.4). All 4 patients with seiz-
ures were therapy responsive and showed a decrease
TABLE 2. Clinical characteristics of progressive myoclonus






Patients, n, F/M 14, (7/7) 8, (6/2)
Age,a IQR 14.5 (7.3-31) 23.5 (18.8-25)
Age of onset disease,a IQR 2 (0.9-2.3) 12 (7-18)
Progressive course 13 5
Duration of disease,a IQR 13.5 (6.3-27) 10.5 (5.3-16)
Duration of follow-up
in years,a IQR
8.8 (2.3-18.2) 3.1 (0.7-4.2)
Myoclonus
Onset acute/gradual/unknown 0/13/1 2/5/1
Distribution (F/A/UL/LL) 7/7/14/8 3/2/8/4
Action induced 11 5
Ataxia
Onset acute/gradual 0/14 -
Distribution (A/UL/LL) 8/13/11 -
Ataxic gait 14 -
Dysarthria 10 -
Infrequent epilepsy 4 1
Cognitive decline (mild/severe) 8 (8/0) 2 (2/0)
Psychiatric symptoms 7 1
Oculomotor abnormalities 9 3
Positive family history 2 1
Etiology
North Sea PME 4 0
SCA 13 2 0






A, axial area; F, face; HADDS, hypotonia ataxia and delayed development
syndrome; IQR, interquartile range; LL, lower limbs; PME, progressive
myoclonus epilepsy; SCA, spinocerebellar ataxia; UL, upper limbs.
aMedian.
FIG. 1. The clinical course of progressive myoclonus ataxia (PMA) and
isolated cortical myoclonus (ICM). The median age of onset, with the
interquartile range (IQR), is displayed for ataxia, myoclonus, and epi-
lepsy, represented by the start of the bar. The length of the bar repre-
sents duration of disease.
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in frequency, resulting in 0 to 1 seizures per year, after
the optimal dose of antiepileptic therapy was initiated.
FigureF1 1 illustrates the clinical course of the 14
patients based on our definition of PMA.
A decline of cognitive function was seen in 8 of 14
PMA patients, all of whom showed mild deterioration.
Associated psychiatric problems were present in 7
cases: an autism spectrum disorder in 3, attention defi-
cit hyperactivity disorder in 2, and behavioral prob-
lems without a diagnosis in 2 cases. In 9 cases,
saccadic oculomotor abnormalities were described. A
positive family history was present in 2 unrelated
patients. The motor symptoms deteriorated over time
in 13 patients, reported by patients as worsening of
daily activity performance, during a median follow-up
period of 8.8 years (IQR 2.3-18.2). During this period,
2 patients became wheelchair bound and 3 patients
used walking aids in daily life.
Polymyography was performed in 8 patients show-
ing an electromyography (EMG) burst duration of
<100 milliseconds, compatible with a cortical origin
of the myoclonus. Additional electrophysiological tests
were obtained in a limited number of these patients,
cortico-coherence analysis was positive in 2/3 cases,
and giant somatosensory evoked potential (SEP) was
present in 0/1 cases, supporting the cortical origin.
EEG was performed in 11 patients. In 4 cases, epilep-
tic abnormalities (ie, multifocal spikes and sharp
waves, with generalization) were observed, and in 5 a
slow background rhythm was observed. In reaction to
a visual stimulation, a photoparoxysmal response was
present in 1 patient, combined with cortical myoclo-
nus. These findings are compatible with cortical reflex
myoclonus. The anatomical origin of myoclonus in the
remaining cases was not further specified and could
not be established based on the retrospective data.
In 9 patients (64%) with PMA, an underlying etio-
logical cause was identified (see Supplemental Table
1). The diagnoses included North Sea PME (n5 4),
spinocerebellar ataxia 5 (n51) and spinocerebellar
ataxia 13 (n52), hypotonia ataxia and delayed devel-
opment syndrome (n51), and nonprogressive congen-
ital cerebellar ataxia (n5 1). In the 5 remaining cases,
no cause could be identified despite the application of
the novel diagnostic myoclonus algorithm, including
the performance of next generation sequencing
(NGS).13 The 2 deceased patients had died before the
myoclonus panel was introduced.
ICM
A total of 8 patients (males, 2; females, 6) with a
median age of 23.5 years (IQR 18.8-25) were diag-
nosed with ICM. Myoclonus was first observed at a
median age of 12 years (IQR 7-18; Figure 1), of which
5 cases showed a gradual onset and 2 (sub)acute; in 1
patient onset was unknown. The myoclonic jerks were
most commonly present in the upper limbs. In 5 cases
the jerks worsened during action. Two patients
showed somatosensory stimulus sensitivity, and in 5
cases negative myoclonus was observed. One patient
had a generalized tonic-clonic seizure at age 40 years.
Mild cognitive decline was observed in 2 patients,
and 1 patient reported depressive symptoms. In 3
patients, abnormal vertical eye movements were seen:
an “around-the-house” sign in 2 cases and saccadic
abnormalities in 1 case. A positive family history was
present in 2 patients. Five patients showed progression
of myoclonus during a median follow-up of 3.1 years
(IQR 0.7-4.2). None of the patients showed deteriora-
tion in walking abilities.
Polymyography in all 8 cases showed a burst dura-
tion of <100 milliseconds. Coherence analysis showed
a cortical origin in 1/4 cases, back averaging in 0/3,
and giant SEP was present in 1/6 cases. EEG showed
both mild epileptic abnormalities (ie, focal spikes) and
mild slow background rhythm in 1 patient; solely epi-
leptic abnormalities (ie, generalized spike and wave
complexes) in 2 patients; and solely a slow back-
ground rhythm in another patient.
No underlying genetic cause could be identified in
any of the patients presenting with ICM despite thor-
ough diagnostic workup. The diagnostic algorithm for
myoclonus has been applied in all cases including
NGS. In 6 cases, NGS was negative, and in 2 it is
pending.
Discussion
In this study, we studied a group of 14 patients
adhering to our refined definition of PMA and
detected a homogenous phenotype with a fixed order
of symptoms. PMA in patients started with ataxia at a
young age (2 years; IQR 1-2.3), with subsequent
occurrence of mainly cortical myoclonus (4 years; IQR
2.3-6), followed by infrequent (treatment responsive)
epilepsy (9.3 years; IQR 6-11.4). The motor symptoms
were progressive in the majority during a median
follow-up period of 8.8 years (IQR 2.3-18.2). Mild
cognitive deterioration was detected in 8 (57%)
patients. In the PMA group, a genetic diagnose was
made in 64% of the patients. In the patients with
ICM, the age at onset of myoclonus is later in early
puberty (12 years; IQR 7-18). In the ICM patients, no
genetic cause was detected.
With the help of our suggested refined definition, we
were able to create a homogenous group of PMA
patients. The underlying etiology in 64% of the PMA
patients is remarkably higher than the previously
reported 50%.4 This high percentage of identified
causes is likely as result of the recent increase of
known genes and the application of NGS. An addi-
tional determinant could be the strict and less
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elaborate PMA definition by the specification of infre-
quent epilepsy and, however less probable, omission
of cognitive decline. The increased percentage of iden-
tified underlying etiologies does not preclude the dis-
covery of new causal molecular defects as 36% of our
PMA cases remain without an etiological diagnosis
despite excessive diagnostic investigations. The
approach of clustering patients with homogenous clin-
ical phenotypes to discover new genes has proven to
be successful in the past by finding a mutation in
GOSR2 causal of North Sea PME.7 The high impact
of identifying such a molecular defect can be observed
as the mutation in GOSR2 accounts for 29% of our
PMA cases. Only by clustering homozygous clinical
phenotypes in our expertise center have we already
identified 3 etiologies and 4 de novo mutations that
broaden the differential diagnosis of PMA for they
had not been previously associated with this syn-
drome. These include spinocerebellar ataxia 5, hypoto-
nia ataxia and delayed development syndrome, and
nonprogressive congenital cerebellar ataxia.
Knowledge regarding the clinical course of PMA
patients is essential to guide clinicians in daily practice.
In patients with childhood-onset ataxia, physicians
should consider the syndrome of PMA in their differen-
tial diagnosis. In the application of childhood-onset
ataxia molecular diagnostic tests, disorders associated
with PMA should be included in sequencing panels or
diagnostic filters. In addition, clinicians should actively
search for the myoclonic jerks in these patients. The
jerks are easily overlooked and sometimes hard to dis-
tinguish from ataxic symptoms, whereas myoclonus can
be medically treated.14 Hopefully this insight into the
clinical course will result in the syndrome of PMA to
be better recognized and treated and the diagnostic
delay for these patients shortened.
Associated symptoms were frequently observed in
PMA patients and mainly included psychiatric symp-
toms and oculomotor abnormalities. Psychiatric
comorbidities have never been scored systematically in
a cohort of PMA patients but are increasingly recog-
nized as clinical features of many genetically deter-
mined movement disorders and generalized
epilepsies.15,16 Furthermore, saccadic eye movement
abnormalities have been described probably related to
the cerebellar ataxia.17 Associated features of underly-
ing etiologies, which were previously described in lit-
erature, were confirmed in our patients as well. The 4
patients identified with GOSR2 presented with are-
flexia and deformities of the feet, although no scoliosis
was seen in our cohort.18 Hypotonia and cognitive
decline were observed as associated features of PMA
caused by a mutation in early B cell factor 3 gene
(EBF3), and speech delay was observed in the patient
with a mutation in the nonprogressive congenital cere-
bellar ataxia gene.19,20
From our data it appears unlikely that ICM is the
predecessor of PMA as only 1 of the PMA patients
started with myoclonic jerks. Furthermore, the age at
onset is later (12 years; IQR 7-18) with a rather
benign course in the ICM group when compared with
the PMA group. The age of onset in the ICM patients
resembled that of the most common form of PME,
Unverricht-Lundborg disease. A recent study describ-
ing 77 Unverricht-Lundborg disease patients showed a
mean age of onset of 11.46 3.2 years.21 Epilepsy is
usually ground for initial referral.22 We focused on
patients referred for movement disorders and excluded
patients with epilepsy as initial reason for referral.
Therefore, it cannot be excluded that the 8 ICM
patients in our study are predecessors of PME. How-
ever, it appears highly unlikely because in only 1 of
the ICM patients, 1 epileptic seizure occurred during
the follow-up of 3.2 years (IQR 0.6-4.5).
Our study has certainly some limitations. To validate
the new proposed criteria for PMA it is important to
compare the novel criteria to the former criteria and
appraise their value in distinguishing PMA from other
neurological syndromes, focusing primarily on PME. In
the current study, PME patients were not included as
our cohort was assembled from the perspective of the
movement disorder specialist. Epilepsy is usually the ini-
tial reason for referral in PME patients,22 and therefore,
including a cohort of patients from an epilepsy clinic is
important for future validation studies of PMA criteria.
Furthermore, the number of patients in our study was
small, with the majority retrospectively identified at a
single tertiary referral center. This warrants a larger
prospective multinational study to increase the sample
size to further delineate the clinical syndrome of PMA
with standardized evaluation, phenotyping the move-
ment disorders in detail and evaluation of the diagnos-
tic yield of molecular testing.
In conclusion, our proposed refined definition of
PMA creates a homogenous group of patients with a
high number of genetic causes, including 3 causes of
PMA not previously reported. Patients with ICM have
a different course and do not appear to evolve in the
PMA syndrome. The suggested definition of PMA
needs further validation, but appears to enable clini-
cians to recognize PMA and make a diagnosis earlier
in life and is also a tool to facilitate future genetic
research.
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